Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us 
About
Not Confirmed
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Not Confirmed
Not Confirmed
07-09 April, 2026
Not Confirmed
Not Confirmed
09-12 April, 2026
List your booth number for exhibitions, ask us 
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
IPhEB Russia
Not Confirmed
Contact SupplierIPhEB Russia
Industry Trade Show
Not Confirmed
07-09 April, 2026
Health 2.0 ConferenceHealth 2.0 Conference
Industry Trade Show
Not Confirmed
07-09 April, 2026
Industry Trade Show
Not Confirmed
09-12 April, 2026
Digital content
NEWS #PharmaBuzz
18 Mar 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/phanes-therapeutics-to-present-three-clinical-posters-at-aacr-2026-302716569.html
10 Jan 2026
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-positive-phase-2-results-of-spevatamig-pt886-in-combination-with-chemotherapy-in-frontline-1l-treatment-of-metastatic-pdac-at-asco-gi-2026-302656945.html
09 Dec 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/phanes-therapeutics-to-present-phase-12-study-results-of-spevatamig-pt886-in-combination-with-chemotherapy-in-frontline-1l-treatment-of-metastatic-pdac-at-asco-gi-2026-302636991.html
08 Sep 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-biliary-tract-carcinoma-btc-patient-dosed-in-clinical-study-of-spevatamig-in-combination-with-chemotherapy-302549488.html
27 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-mavrostobart-pt199-in-combination-with-chemotherapy-302464552.html
05 May 2025
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/phanes-therapeutics-announces-first-patient-dosed-in-clinical-study-of-peluntamig-in-combination-with-atezolizumab-302446359.html
Drugs in Development
Details:
PT217 (peluntamig) in combination with Roche's anti-PD-L1 monoclonal antibody atezolizumab (TECENTRIQ® ) is being investigated in patients with extensive-stage small cell lung cancer.
Lead Product(s): Peluntamig,Atezolizumab,Carboplatin
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable May 05, 2025
Lead Product(s) : Peluntamig,Atezolizumab,Carboplatin
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Inapplicable
Deal Type : Inapplicable
Phanes Starts Peluntamig Plus Atezolizumab Clinical Study in Cancer
Details : PT217 (peluntamig) in combination with Roche's anti-PD-L1 monoclonal antibody atezolizumab (TECENTRIQ® ) is being investigated in patients with extensive-stage small cell lung cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
May 05, 2025
Details:
PT217 (peluntamig) is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with neuroendocrine prostate carcinoma.
Lead Product(s): Peluntamig,Carboplatin,Etoposide
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable February 19, 2025
Lead Product(s) : Peluntamig,Carboplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phanes Doses First Patient in Peluntamig (PT217) Combo Study
Details : PT217 (peluntamig) is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with neuroendocrine prostate carcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
February 19, 2025
Details:
PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with neuroendocrine prostate carcinoma.
Lead Product(s): Peluntamig
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable December 04, 2024
Lead Product(s) : Peluntamig
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phanes Therapeutics' PT217 Granted Fast Track Designation by the FDA for NEPC
Details : PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with neuroendocrine prostate carcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
December 04, 2024
Details:
PT-886 is a first-in-class native IgG-like bispecific antibody targeting claudin 18.2 & CD47, is being developed for the treatment of gastric, gastroesophageal junction and pancreatic adenocarcinomas.
Lead Product(s): PT886,Oxaliplatin,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 09, 2024
Lead Product(s) : PT886,Oxaliplatin,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phanes Therapeutics Doses First Patient in PT886 Study Combined with Chemotherapy
Details : PT-886 is a first-in-class native IgG-like bispecific antibody targeting claudin 18.2 & CD47, is being developed for the treatment of gastric, gastroesophageal junction and pancreatic adenocarcinomas.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 09, 2024
Details:
PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with neuroendocrine carcinoma.
Lead Product(s): Peluntamig
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable August 16, 2024
Lead Product(s) : Peluntamig
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phanes Therapeutics’ PT217 Receives Orphan Drug Designation for Neuroendocrine Carcinoma
Details : PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with neuroendocrine carcinoma.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
August 16, 2024
Details:
The agreement aims to study PT217, a bispecific antibody targeting DLL3 and CD47, in combo with Roche's atezolizumab for SCLC and neuroendocrine carcinomas.
Lead Product(s): Peluntamig,Atezolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: IND EnablingProduct Type: Antibody, Unconjugated
Sponsor: F. Hoffmann-La Roche
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement May 08, 2024
Lead Product(s) : Peluntamig,Atezolizumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : F. Hoffmann-La Roche
Deal Size : Undisclosed
Deal Type : Agreement
Phanes Partners with Roche To Evaluate PT217 with Anti-PD-L1 Therapy
Details : The agreement aims to study PT217, a bispecific antibody targeting DLL3 and CD47, in combo with Roche's atezolizumab for SCLC and neuroendocrine carcinomas.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
May 08, 2024
Details:
PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with extensive-stage small cell lung cancer.
Lead Product(s): Peluntamig
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable April 08, 2024
Phanes Therapeutics' PT217 granted Fast Track Designation by the FDA
Details : PT217 is a first-in-class native IgG-like bispecific antibody (bsAb) targeting DLL3 and CD4. It is being evaluated for the treatment of patients with extensive-stage small cell lung cancer.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
April 08, 2024
Details:
PT886 is a first-in-class bispecific antibody targeting claudin 18.2 and CD47, being developed for gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
Lead Product(s): PT886,Pembrolizumab,Pemetrexed
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase I/ Phase IIProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable March 20, 2024
Lead Product(s) : PT886,Pembrolizumab,Pemetrexed
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Phanes Therapeutics’ PT886 Receives Fast Track Designation for Pancreatic Cancer
Details : PT886 is a first-in-class bispecific antibody targeting claudin 18.2 and CD47, being developed for gastric, gastroesophageal junction, and pancreatic adenocarcinomas.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
March 20, 2024
Details:
The collaboration aims to study PT886, a first-in-class bispecific antibody targeting claudin 18.2 and CD47, in combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with claudin 18.2 positive gastric or gastroesophageal junction adenocarcinomas.
Lead Product(s): PT886,Pembrolizumab
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Merck & Co
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Collaboration October 16, 2023
Lead Product(s) : PT886,Pembrolizumab
Therapeutic Area : Oncology
Highest Development Status : Phase I
Partner/Sponsor/Collaborator : Merck & Co
Deal Size : Undisclosed
Deal Type : Collaboration
Details : The collaboration aims to study PT886, a first-in-class bispecific antibody targeting claudin 18.2 and CD47, in combination with Merck's anti-PD-1 therapy, Keytruda (pembrolizumab), in patients with claudin 18.2 positive gastric or gastroesophageal junct...
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Undisclosed
October 16, 2023
Details:
PT217 is a common light chain bispecific antibody discovered through Phanes' research engine and was granted orphan drug designation (ODD) for the treatment of small cell lung cancer by the FDA last year.
Lead Product(s): Peluntamig
Therapeutic Area: Oncology Brand Name: Undisclosed
Study Phase: Phase IProduct Type: Antibody, Unconjugated
Sponsor: Undisclosed
Deal Size: Inapplicable Upfront Cash: Inapplicable
Deal Type: Inapplicable September 07, 2023
Details : PT217 is a common light chain bispecific antibody discovered through Phanes' research engine and was granted orphan drug designation (ODD) for the treatment of small cell lung cancer by the FDA last year.
Product Name : Undisclosed
Product Type : Antibody, Unconjugated
Upfront Cash : Inapplicable
September 07, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]REF. STANDARDS & IMPURITIES
ABOUT THIS PAGE
Share 
